- Home
- HDL vs ELVN Comparison
HDL vs ELVN Comparison
Compare HDL & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HDL
- ELVN
- Stock Information
- Founded
- HDL 2016
- ELVN 2016
- Country
- HDL Singapore
- ELVN United States
- Employees
- HDL N/A
- ELVN N/A
- Industry
- HDL Restaurants
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- HDL Consumer Discretionary
- ELVN Health Care
- Exchange
- HDL Nasdaq
- ELVN Nasdaq
- Market Cap
- HDL 1.2B
- ELVN 1.2B
- IPO Year
- HDL 2024
- ELVN 2020
- Fundamental
- Price
- HDL $20.30
- ELVN $19.32
- Analyst Decision
- HDL
- ELVN Strong Buy
- Analyst Count
- HDL 0
- ELVN 5
- Target Price
- HDL N/A
- ELVN $41.20
- AVG Volume (30 Days)
- HDL 4.3K
- ELVN 410.5K
- Earning Date
- HDL 08-26-2025
- ELVN 08-12-2025
- Dividend Yield
- HDL N/A
- ELVN N/A
- EPS Growth
- HDL 110.82
- ELVN N/A
- EPS
- HDL 0.06
- ELVN N/A
- Revenue
- HDL $789,766,000.00
- ELVN N/A
- Revenue This Year
- HDL $17.95
- ELVN N/A
- Revenue Next Year
- HDL $13.32
- ELVN N/A
- P/E Ratio
- HDL $34.92
- ELVN N/A
- Revenue Growth
- HDL 10.91
- ELVN N/A
- 52 Week Low
- HDL $13.94
- ELVN $13.30
- 52 Week High
- HDL $30.00
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- HDL N/A
- ELVN 40.65
- Support Level
- HDL N/A
- ELVN $21.25
- Resistance Level
- HDL N/A
- ELVN $22.83
- Average True Range (ATR)
- HDL 0.00
- ELVN 1.42
- MACD
- HDL 0.00
- ELVN -0.35
- Stochastic Oscillator
- HDL 0.00
- ELVN 5.60
About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares
Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. It mission is to become a global integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.